UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

            

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER

THE  SECURITIES EXCHANGE ACT OF 1934

For the Month of   June 2012            

File No.   000-54598

Stellar Biotechnologies Inc.

(Name of Registrant)

332 E. Scott Street, Port Hueneme, CA 93041

 (Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F __X__

FORM 40-F  ______

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ___

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.

(Registrant)

Dated: June 26, 2012	By:  /s/  "Darrell Brookstein" Darrell Brookstein Director

Exhibits:

99.1

News Release dated June 25, 2012

Stellar Biotechnologies to Present at ImVacS 2012 Summit on August 13 - 16, 2012

PORT HUENEME, CA, (June 25, 2012) -- Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is pleased to report that an abstract prepared by Stellar scientists on KLH immunobiology has been accepted for presentation at the prestigious ImVacS 2012 Summit (The Immunotherapeutics & Vaccine Summit) August 13 - 16, 2012 in Cambridge, MA - www.imvacs.com) in a poster presentation entitled “Keyhole Limpet Hemocyanin (KLH): A Unique, Unlikely Pharmaceutical Product.”

Stellar’s Herbert Chow, Ph.D., John Sundsmo, Ph.D. and Martin Sagermann, Ph.D.  initiated and developed this work, and the Company will post the presentation on www.KLHSite.com after the conference.

About the ImVacS 2012 SUMMIT  (www.imvacs.com)

Each year, ImVacS brings together vaccine professionals from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccine innovation stands today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations.

About Stellar Biotechnologies, Inc. (www.StellarBiotech.com)

Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) (Frankfort: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

Contact:

Frank Oakes, President & CEO

foakes@stellarbiotech.com

Main +1 (805) 488-2800

 

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.